Brief: CERo Therapeutics Announces Third Dose for Patient in Phase 1 Clinical Trial of CER-1236 in AML
21/10/2025 13:29
Oct 21 (Reuters) - CERo Therapeutics Holdings Inc CERO.O: CERO THERAPEUTICS ANNOUNCES THIRD DOSE FOR PATIENT IN PHASE 1 CLINICAL TRIAL OF CER-1236 IN AML Source text: ID:nGNX4xZJjk Further company coverage: CERO.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on CERo Therapeutics Holdings
See all newsBrief: Cero Therapeutics Hearing Review Council Issued Decision
Brief: Cero Therapeutics Provides Clinical Update On Phase 1 Trial Of Cer-1236 In Aml (Certaint-1)
Brief: Cero Therapeutics Provides Clinical Update On Phase 1 Trial Of Cer-1236 In Aml
Brief: Cero Therapeutics Provides Clinical Update On Phase 1 Clinical Trial
Brief: Cero Therapeutics Holdings Inc - Continues To Evaluate Additional Options For Up-List